

David Y Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4158623/publications.pdf>

Version: 2024-02-01

18
papers

1,094
citations

759233

12
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

1596
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362. | 30.7 | 132 |
| 2 | Somatic Dnmt3a inactivation leads to slow, canonical DNA methylation loss in murine hematopoietic cells. <i>iScience</i> , 2022, 25, 104004. | 4.1 | 2 |
| 3 | Dnmt3a deficiency in the skin causes focal, canonical DNA hypomethylation and a cellular proliferation phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2022760118. | 7.1 | 6 |
| 4 | Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome. <i>Nature Communications</i> , 2021, 12, 4549. | 12.8 | 21 |
| 5 | Remethylation of <i>Dnmt3a</i> hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3123-3134. | 7.1 | 27 |
| 6 | Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 742-746. | 1.3 | 18 |
| 7 | Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation. <i>Oncotarget</i> , 2020, 11, 4836-4844. | 1.8 | 9 |
| 8 | A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. <i>Nature Communications</i> , 2019, 10, 3660. | 12.8 | 147 |
| 9 | DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line. <i>Blood Cancer Journal</i> , 2018, 8, 38. | 6.2 | 7 |
| 10 | A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas. <i>Cell Death and Disease</i> , 2016, 7, e2406-e2406. | 6.3 | 72 |
| 11 | Physicians judging medical negligence: A conflict of values. <i>Surgery</i> , 2015, 157, 818-823. | 1.9 | 0 |
| 12 | A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth. <i>Cancer Research</i> , 2012, 72, 736-746. | 0.9 | 40 |
| 13 | Targeting Taspase1 for Cancer Therapy Response. <i>Cancer Research</i> , 2012, 72, 2913-2913. | 0.9 | 5 |
| 14 | Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis. <i>Cancer Research</i> , 2010, 70, 5358-5367. | 0.9 | 41 |
| 15 | The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1093-1098. | 7.1 | 107 |
| 16 | Design, syntheses, and evaluation of Taspase1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5086-5090. | 2.2 | 35 |
| 17 | Proteolysis of MLL family proteins is essential for Taspase1-orchestrated cell cycle progression. <i>Genes and Development</i> , 2006, 20, 2397-2409. | 5.9 | 142 |
| 18 | Proteomic Analysis Reveals Hyperactivation of the Mammalian Target of Rapamycin Pathway in Neurofibromatosis 1 Associated Human and Mouse Brain Tumors. <i>Cancer Research</i> , 2005, 65, 2755-2760. | 0.9 | 283 |